Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.
Tatsuya KikuchiYasuto TakeuchiKazuhiro NousoKazuya KariyamaKenji KuwakiJunichi ToshimoriShota IwadoAkio MoriyaHiroaki HagiharaHiroyuki TakabatakeToshifumi TadaTetsuya YasunakaMasahiro SakataMasahiko SueNozomi MiyakeTakuya AdachiNozomu WadaHideki OnishiHidenori ShirahaAkinobu TakakiMotoyuki OtsukaPublished in: Liver international : official journal of the International Association for the Study of the Liver (2024)
BCLC stage was the sole predictive factor for successful transition to conversion therapy when using combination therapy with atezolizumab and bevacizumab to treat HCC. Furthermore, a small number of intrahepatic lesions and early transition to conversion therapy were associated with the achievement of cancer-free status.